Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy

Erectile Dysfunction Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00895011
• Other study ID #: TA-303
• Status: Completed
• Phase: Phase 3
• First received: May 5, 2009
• Last updated: September 14, 2012
• Start date: April 2009
• Est. completion date: April 2011

Study information

• Verified date: September 2012
• Source: VIVUS, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The objectives of this study are to evaluate the safety and efficacy of two doses of avanafil in the treatment of adult males for erectile dysfunction following bilateral nerve-sparing radical prostatectomy.

Other known NCT identifiers

• NCT01171001

Recruitment information / eligibility

• Status: Completed
• Enrollment: 298
• Est. completion date: April 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Adult males = 18 years and = 70 years;

• Have a history of erectile dysfunction of at least 6 months duration following bilateral nerve-sparing retropubic radical prostatectomy;

• Have a PSA level consistent with the absence of prostate cancer;

• Have a history of sexual potency prior to radical prostatectomy without requiring medical therapy;

• Be in a monogamous, heterosexual relationship with their current partner for at least 3 months;

• Provide written informed consent;

• Agree to make at least 4 attempts at intercourse per month;

• Agree not to use any other treatments for erectile dysfunction;

• Be willing and able to comply with all study requirements (including scheduled study visits, treatment plans, laboratory tests and other study procedures).

Exclusion Criteria

• Allergy or hypersensitivity to PDE5 inhibitors or any of the components of these drug products;

• History of dose-limiting AEs during prior treatment with a PDE5 inhibitor or discontinued use of a PDE5 inhibitor due to lack of efficacy at the highest tolerated dose;

• Concomitant use of one or more of the following medications:

• Any nitrate, trazodone, itraconazole, ketoconazole, erythromycin, or cimetidine;

• Other prescription or OTC drugs that are known to interfere with metabolism by the CYP 3A4 enzyme;

• If receiving hormone replacement therapy (including thyroid supplementation), dose that has not been stable for at least 3 months;

• If treated with an alpha blocker, dose that has not been stable for at least 14 days;

• Erectile dysfunction as a consequence of advanced neurologic disease, spinal cord injury, or diabetes;

• History of severe erectile dysfunction requiring medical therapy prior to bilateral nerve-sparing radical prostatectomy;

• History of previous pelvic surgery, brachytherapy, or cryotherapy of the prostate;

• Sexual partner who is under 18 years of age, pregnant, intends to become pregnant during the course of the study, is breastfeeding, has dyspareunia or other gynecologic conditions or other major medical conditions that would interfere with sexual activity or would have difficulty complying with study requirements;

• Uncontrolled hypertension;

• Hypotension;

• Orthostatic hypotension;

• Myocardial infarction, stroke, life-threatening arrhythmia or coronary revascularization within the past 6 months;

• Unstable angina, angina with sexual intercourse, or congestive heart failure > NYHA Class II;

• History or ECG evidence of any high-risk arrhythmia or clinically significant ECG;

• Hypertrophic, obstructive, or other clinically significant cardiomyopathy, moderate or severe cardiac valvular disease;

• Type 1 or type 2 diabetes, history of use of any antidiabetic medication;

• Clinically evident penile lesions, abrasions, anatomical deformities such as penile fibrosis, Peyronie's disease, penile implants, urinary tract or bladder infection, or sexually transmissible disease that the investigator deems to be clinically significant;

• Condition(s) predisposing to priapism, such as sickle cell disease , multiple myeloma, or leukemia;

• Any malignancy other than carcinoma of the prostate (except basal cell carcinoma or squamous cell carcinoma of the skin);

• Prior use of, or likely to require radiotherapy, chemotherapy, androgen deprivation therapy, cryotherapy, non-nerve-sparing surgery, and/or bladder or penile surgery during the study;

• Evidence of significant hepatic impairment;

• On dialysis, or history of renal transplantation;

• Untreated hypogonadism or low serum total testosterone;

• Abnormal laboratory value(s) judged to be clinically significant by the investigator;

• Positive STD screen (syphilis, gonorrhea, or chlamydia);

• Positive for HIV, HCV Ab, or HBsAg at screening;

• History or current drug, alcohol, or substance abuse;

• Positive urine drug screen;

• Positive breath alcohol test;

• Retinitis pigmentosa or nonarteritic anterior ischemic optic neuropathy;

• Use of any treatment or device for treatment of erectile dysfunction;

• Use of any other investigational medication or device for any indication within 30 days prior to enrollment or at any time during this study;

• Previous participation in any other investigational study of avanafil;

• Any history of bipolar disorder or psychosis, greater than one lifetime episode of major depression, current depression of moderate or greater severity or antidepressant use that has not been stable for at least 3 months;

• Involvement in the planning and conduct of the study on the part of subject or partner;

• Evidence of any clinically significant medical, psychiatric, social or other condition by history, physical examination or laboratory studies that, in the opinion of the investigator, would contraindicate the administration of study medications, affect compliance, interfere with study evaluations, limit study participation, contraindicate sexual activity or confound the interpretation of study results.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Erectile Dysfunction

Intervention

Drug:
• Placebo
One dose 30 minutes prior to initiation of sexual activity
• Avanafil
One dose 30 minutes prior to initiation of sexual activity
• Avanafil
One dose 30 minutes prior to initiation of sexual activity

Locations

Country	Name	City	State
United States	Research Site	Ann Arbor	Michigan
United States	Research Site	Arlington	Texas
United States	Research Site	Aurora	Colorado
United States	Research Site	Bala Cynwyd	Pennsylvania
United States	Research Site	Baltimore	Maryland
United States	Research Site	Brighton	Massachusetts
United States	Research Site	Brooklyn	New York
United States	Research Site	Brooklyn	New York
United States	Research Site	Burlington	Massachusetts
United States	Research Site	Charlottesville,	Virginia
United States	Research Site	Chicago	Illinois
United States	Research Site	Chicago	Illinois
United States	Research Site	Cincinnati	Ohio
United States	Research Site	Cleveland	Ohio
United States	Research Site	Durham	North Carolina
United States	Research Site	Englewood	Colorado
United States	Research Site	Fairfax	Virginia
United States	Research Site	Garden City	New York
United States	Research Site	Great Neck	New York
United States	Research Site	Greensboro	North Carolina
United States	Research Site	Hackensack	New Jersey
United States	Research Site	Houston	Texas
United States	Research Site	Indianapolis	Indiana
United States	Research Site	Jacksonville	Florida
United States	Research Site	Jamaica Plain	Massachusetts
United States	Research Site	Laguna Hills	California
United States	Research Site	Lawrenceville	New Jersey
United States	Research Site	Los Angeles	California
United States	Research Site	Los Angeles	California
United States	Research Site	Miami	Florida
United States	Research Site	Myrtle Beach	South Carolina
United States	Research Site	Nashville	Tennessee
United States	Research Site	New Orleans	Louisiana
United States	Research Site	New York	New York
United States	Research Site	New York	New York
United States	Research Site	New York	New York
United States	Research Site	Parker	Colorado
United States	Research Site	Philadelphia	Pennsylvania
United States	Research Site	Philadelphia	Pennsylvania
United States	Research Site	Phoenix	Arizona
United States	Research Site	Poughkeepsie	New York
United States	Research Site	Richmond	Virginia
United States	Research Site	Rock Hill	South Carolina
United States	Research Site	Sacramento	California
United States	Research Site	San Antonio	Texas
United States	Research Site	Shreveport	Louisiana
United States	Research Site	Springfield	Illinois
United States	Research Site	Temple	Texas
United States	Research Site	Towson	Maryland
United States	Research Site	Trinity	Florida
United States	Research Site	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
VIVUS, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Percentage of Sexual Attempts in Which Subjects Are Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse	Data presented as mean change from baseline in the percentage of Yes responses to Sexual Encounter Profile (SEP) diary question 3 "Did your erection last long enough for you to have successful intercourse?"	Baseline, Week 12	No
Primary	The Change in Percentage of Sexual Attempts in Which Subjects Are Able to Insert the Penis Into the Partner's Vagina	Data presented as mean change from baseline in the percentage of Yes responses to Sexual Encounter Profile (SEP) diary question 2 "Were you able to insert your penis into your partner's vagina?"	Baseline, Week 12	No
Primary	Change in International Index of Erectile Function - Erectile Function Domain (IIEF-EF) Score	Questionnaire assesses subject's evaluation of erectile function over the previous 4-week period. Total scores from questions 1-5 & 15 range from 1 to 30. A higher score indicates better erectile function.	Baseline, End of Treatment (up to 12 weeks)	No